Johnson & Johnson (NYSE:JNJ) Stake Raised by Sheets Smith Wealth Management

Sheets Smith Wealth Management increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,935 shares of the company’s stock after purchasing an additional 114 shares during the period. Sheets Smith Wealth Management’s holdings in Johnson & Johnson were worth $2,204,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. Christopher J. Hasenberg Inc acquired a new stake in shares of Johnson & Johnson during the 1st quarter valued at $31,000. Keener Financial Planning LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at $40,000. WFA Asset Management Corp lifted its position in shares of Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after acquiring an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at $44,000. Finally, Disciplined Equity Management Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at $45,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded up $5.57 during mid-day trading on Wednesday, hitting $156.58. The company had a trading volume of 13,795,328 shares, compared to its average volume of 7,313,591. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. The business’s 50-day simple moving average is $148.00 and its 200-day simple moving average is $153.37. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The firm has a market cap of $376.84 billion, a P/E ratio of 9.70, a PEG ratio of 2.51 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. During the same quarter in the prior year, the business posted $2.80 earnings per share. The company’s quarterly revenue was up 4.3% compared to the same quarter last year. As a group, analysts predict that Johnson & Johnson will post 10.49 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.17%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on JNJ shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research note on Monday, June 17th. The Goldman Sachs Group started coverage on shares of Johnson & Johnson in a research note on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price target on the stock. Bank of America lowered their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, July 1st. Finally, HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $174.07.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.